Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations

Sun Wei; Ding XiaoYan; Chen JingLong

doi:10.3969/j.issn.1001-5256.2016.12.021

Issue 12

Dec. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(12): 2337-2341

PDF( 1689 KB)

Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations

DOI: 10.3969/j.issn.1001-5256.2016.12.021

Research funding:

Published Date: 2016-12-20

Abstract

Abstract

Objective To investigate the clinical effect and safety of percutaneous radiofrequency ablation( RFA) following transcatheter arterial chemoembolization( TACE) in the treatment of primary liver cancer in high- risk locations. Methods The patients with primary liver cancer in high- risk locations who were diagnosed and treated from January 2011 to December 2015 were enrolled. All the patients underwent TACE followed by CT- guided RFA 3- 5 days later. The treatment outcome and adverse events were observed. Results A total of64 patients with 76 lesions were enrolled and all of them completed TACE and RFA. At one month after surgery,the complete tumor ablation rate was 81. 5%( 62/76). The patients were followed up for 6 to 64 months after surgery; at the end of follow- up,the local tumor progression rate was 28. 9%( 22/76),and the 1-,2-,and 3- year survival rates were 90. 6%,78. 1%,and 64. 1%,respectively. The incidence rate of severe surgical complications during follow- up was 3. 1%( one patient each experienced liver abscess and hematobilia),and the patients achieved remission after medical treatment and interventional treatment without any sequel. Conclusion CT- guided RFA after TACE is a safe and feasible regimen for primary liver cancer in high- risk locations.
- liver neoplasms,
- chemoembolization,therapeutic,
- catheter ablation,
- postoperative complications,
- treatment outcome

FullText(HTML)

References(18)

References

[1]WANG Y,LUO Q,LI Y,et al.Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas:a meta-analysis of randomized and non randomized controlled trials[J].PLo S One,2014,9(1):e84484.

[2]TERATANI T,YOSHIDA H,SHIINA S,et al.Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J].Hepatology,2006,43(5):1101-1108.

[3]LIU LL.The development of radiofrequency ablation of hepatic carcinoma in high-risk locations[J].Chin Clin Oncol,2012,17(5):475-478.(in Chinese)刘丽莉.高危部位肝癌射频消融治疗的进展[J].临床肿瘤学杂志,2012,17(5):475-478.

[4]Ministry of Health of the People’s Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[5]BRUIX J,SHERMAN M,LLOVET JM,et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol,2001,35(3):421-430.

[6]GOLDBERG SN,CHARBONEAU JW,DODD GD,et al.Imageguided tumor ablation:proposal for standardization of terms and reporting criteria[J].Radiology,2003,228(2):335-345.

[7]de LIMA LOPES GJR,DICKSEY JS,PETERS WP,et al.Final results of a prematurely discontinued phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma[J].Cancer Chemother Pharmacol,2011,68(4):1067-1073.

[8]GAZELLE GS,GOLDBERG SN,SOLBIATI L,et al.Tumor ablation with radio-frequency energy[J].Radiology,2000,217(3):633-646.

[9]WONG SN,LIN CJ,LIN CC,et al.Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J].AJR Am J Roentgenol,2008,190(3):w187-195.

[10]CHA DI,LEE MW,RHIM H,et al.Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations[J].Korean J Radiol,2013,14(2):240-247.

[11]LIN JW,LIN CC,CHEN WT,et al.Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma(3.1-4cm)and in high-risk locations[J].Kaohsiung J Med Sci,2014,30(8):396-401.

[12]KELOGRIGORIS M,LASPAS F,KYRKOU K,et al.Percutaneous radiofrequency ablation for malignant liver tumours in challenging locations[J].J Med Imaging Radiat Oncol,2012,56(1):48-54.

[13]YAMANAKA T,YAMAKADO K,TAKAKI H,et al.Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas[J].Jpn J Radiol,2012,30(7):553-559.

[14]ZHANG L,YIN X,GAN YH,et al.Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria[J].BMC Gastroenterol,2014,14(1):11.

[15]YI Y,ZHANG Y,WEI Q,et al.Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone[J].Chin J Cancer Res,2014,26(1):112-118.

[16]DU JK,ZHANG MD,ZOU Y,et al.Large dose heat lipiodol TACE combined with radiofrequency ablation in treatment of hepatic metastases of digestive tract cancer[J].Clin J Med Offic,2014,42(9):898-900.(in Chinese)独建库,张明德,邹洋,等.大剂量热碘的TACE联合射频消融术治疗消化道癌肝转移[J].临床军医杂志,2014,42(9):898-900.

[17]BILCHIK AJ,WOOD TF,ALLEGRA D,et al.Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms:a proposed algorithm[J].Arch Surg,2000,135(6):657-662.

[18]LI M,LI ZY,TIAN JK,et al.Clinical study of ultrasound-guided percutaneous radiofrequency ablation for primary hepatic carcinoma adjacent to the diaphragm[J].J Clin Hepatol,2015,31(4):573-577.(in Chinese)李猛,李志艳,田江克,等.超声引导经皮射频消融对邻近横膈部原发性肝癌治疗的有效性与安全性评价[J].临床肝胆病杂志,2015,31(4):573-577.

Relative Articles

[1]	Guozhi WU, Guohong WU, Xianglei ZHANG, Guangzhi DING, Lei WANG. Severe drug-induced hypersensitivity syndrome in patients with liver cirrhosis and epilepsy induced by lamotrigine: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1907-1908. doi: 10.3969/j.issn.1001-5256.2021.08.032
[2]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[3]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[4]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[5]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[6]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[7]	Bai Xue, Ma ZuoHong, Hao ZhiQiang, Fu XiBo, Jiao Ao, Shang Hai, Hua XiangDong. Research advances in the risk factors for microvascular invasion in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2578-2581. doi: 10.3969/j.issn.1001-5256.2019.11.042
[8]	Zhang Dan, Feng GuoHe. Current research status of nosocomial infection in patients with severe liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(1): 213-216. doi: 10.3969/j.issn.1001-5256.2019.01.047
[9]	Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
[10]	Lin YunXia, He XiaoBin. Clinical features of drug-induced liver injury and related risk factors[J]. Journal of Clinical Hepatology, 2018, 34(6): 1237-1241. doi: 10.3969/j.issn.1001-5256.2018.06.021
[11]	Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
[12]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[13]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[14]	Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
[15]	Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018
[16]	Ye ChuanTao, Wei Xin, Zhang Ying. Current status of research on liver innate immunity[J]. Journal of Clinical Hepatology, 2014, 30(9): 846-850. doi: 10.3969/j.issn.1001-5256.2014.09.003
[17]	Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
[18]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[19]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 闫红会，张二娟，徐心红. 半坐卧位深部保留灌肠对肝性脑病患者的影响. 内蒙古医学杂志. 2023(11): 1386-1388+1391 .
Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2128) PDF downloads(420)

Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations

DOI: 10.3969/j.issn.1001-5256.2016.12.021

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations

DOI: 10.3969/j.issn.1001-5256.2016.12.021

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content